INTRODUCTION
Genome-wide association studies have revealed a strong association between DNA sequence variation on chromosome 9p21 and the risk of coronary artery disease (CAD) (1 -4) . This has been confirmed in many independent studies (5 -8) . Additionally, this genetic locus has been shown to be associated with abdominal aortic aneurysm (9) , intracranial aneurysm (9 -11), carotid atherosclerosis (12) , ischaemic stroke (13) and peripheral vascular disease (14) . On the other hand, there is no association between this locus and classic CAD-related intermediate traits such as hyperlipidaemia and hypertension (5, 6, 12, 15) . The mechanism by which variation at this locus influences the risk of CAD is currently unclear.
The 9p21 locus contains multiple CAD-associated singlenucleotide polymorphisms (SNPs) in strong linkage disequilibrium, spanning a genomic region of over 50 kb (1 -5) . This genomic interval does not contain any protein-coding sequences; however, near this interval reside the cyclindependent kinase 2A (CDKN2A) and 2B (CDKN2B) genes (1 -5) which encode the cell proliferation regulators p16 INK4a (by exons 1a, 2 and 3 of the CDKN2A gene), p14 ARF (by exons 1b and 2 of the CDKN2A gene) and p15 INK4b (by the CDKN2B gene) (16) . In addition, this genomic interval contains a gene for a non-coding RNA † The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors. known as ANRIL (antisense non-coding RNA in the INK4 locus) (1-5) which may have a role in the regulation of CDKN2A and CDKN2B expression (17, 18) .
Recently, it has been demonstrated that targeted deletion of the orthologous interval in mice resulted in a significant reduction in cardiac expression of CDKN2A and CDKN2B (19) , indicating that this genomic interval harbours regulatory elements that modulate the expression of these genes. In addition, the study showed that primary cultures of vascular smooth muscle cells (VSMCs) from mice with the deletion of the orthologous interval exhibited excessive proliferation, presumably due to altered CDKN2A and CDKN2B expression (19) . Since VSMCs play important roles in atherosclerosis (20) , these findings point to a possible mechanism for the association of the 9p21 locus with susceptibility to CAD in humans, such that the CAD-associated variant at this locus might modulate CDKN2A and CDKN2B expression in VSMCs, thereby affecting VSMC proliferation and consequently the development and progression of atherosclerosis.
In the present study, we investigated whether there was a relationship between the 9p21 locus SNP rs1333049 which had been repeatedly associated with risk of CAD (1, 6, 7) , and expression levels of CDKN2A, CDKN2B and ANRIL in primary cultures of VSMCs, and if the SNP was also associated withcoding RNA ANRIL (17, (21) (22) (23) . There is evidence indicating that ANRIL plays a role in the transcriptional regulation of CDKN2A and CDKN2B (18, 24) , and studies in blood cells and vascular tissues have shown that CDKN2A and CDKN2B expression levels are correlated with ANRIL levels (17, 22, 23, 25) . Therefore, we investigated whether there was an association between the SNP rs1333049 genotype and ANRIL expression in VSMCs and ascertained relationships of ANRIL with p16
INK4a , p14 ARF and p15 INK4b in these cells. We detected an association between the SNP and ANRIL expression, with cells of the C/C genotype having lowest levels (P ¼ 3.1 × 10 29 ; Fig. 3A ). In addition, we observed correlations between ANRIL and p16
INK4a , p14 ARF and p15
INK4b expression levels (r ¼ 0.744, 0.348 and 0.352, respectively; Fig. 3B-D) .
Association between 9p21 variation and VSMC proliferation in culture
Since p16
INK4a and p15 INK4b are negative regulators of cell cycle and proliferation (16, 26, 27) , we investigated whether the levels of the cell proliferation marker PCNA (proliferating cell nuclear antigen) were associated with p16
INK4a and p15
INK4b levels and with the SNP rs1333049 genotype, in VSMCs. We observed an inverse relationship of PCNA with Fig. 4B ). Importantly, we found that PCNA levels were significantly associated with the SNP rs1333049 genotype, being highest in VSMCs of the C/C genotype (P ¼ 2.3 × 10 22 ; Fig. 4C ). Further to the above analyses, we examined whether the 9p21 variant was associated with VSMC proliferation. We performed proliferation assays in another collection of VSMCs from umbilical cords (n ¼ 73). This experiment showed an association between SNP rs1333049 and VSMC proliferation, with cells of the C/C genotype having highest values (P ¼ 1.6 × 10
22
; Fig. 5 The analysis showed that the percentages of p15
INK4b stain areas were lower in individuals carrying the C allele of SNP rs1333049 (P ¼ 3.7 × 10 22 ; Fig. 6B ) and there was a similar trend for p16
INK4a (P ¼ 6.5 × 10
; Fig. 6A ).
Association between 9p21 variation and VSMC content in atherosclerotic plaques
Further to the above analysis, we investigated whether there was a relationship of the 9p21 variation with the abundance of proliferating VSMCs and with VSMC content in atherosclerotic plaques. We performed double immunostaining of SMA and the cell proliferation marker Ki67 in coronary atherosclerotic plaques from different individuals (n ¼ 52). We found an association between SNP rs1333049 and VSMC content, with atherosclerotic plaques of the C/C genotype having the highest VSMC content (P ¼ 5.6 × 10
24
; Fig. 7 ). Additionally, we observed that plaques of the C/C genotype had a non-significant trend towards higher percentages of Ki67-positive SMCs (Supplementary Material, Fig. S2 ).
DISCUSSION
Following the finding from genome-wide association studies and many replication studies that variation at the 9p21 locus is a major genetic determinant for CAD (1 -8) , there have been considerable efforts aimed at elucidating the underlying mechanisms. Further to findings from previous studies by other groups (17) (18) (19) (21) (22) (23) 25, 28) , our present study has provided several lines of new information. Our study shows that in primary cultures of VSMCs, there is an association of 9p21 genotype with CDKN2A, CDKN2B and ANRIL expression levels and with the rate of proliferation. Furthermore, our study reveals a relationship of 9p21 genotype with p15
INK4b levels in VSMCs in atherosclerotic plaques and with VSMC content in the plaques. These findings provide new insight into the mechanism underlying the association between variation at the 9p21 locus and risk of CAD. p16 INK4a and p15 INK4b encoded by CDKN2A and CDKN2B, respectively, are known to play important roles in regulating the cell cycle in many cell types (16) . They inhibit cell proliferation by suppressing dissociation of the transcription factor E2F from retinoblastoma protein and consequently suppressing E2F-mediated expression of cell proliferation genes (16) . Findings from animal models indicate that these cell cycle regulators repress VSMC proliferation in the blood vessel wall (29) (30) (31) , although it is still unclear whether they exert similar effects in the human vasculature.
Previous studies in human peripheral blood T-lymphocytes (21), peripheral blood mononuclear cells (22) and whole peripheral blood cells (17, 22, 23) showed a relationship of CAD-associated SNPs at the 9p21 locus with expression levels of CDKN2A, CDKN2B and/or ANRIL. In another study of peripheral blood mononuclear cells, however, CDKN2A and ANRIL were undetectable and CDKN2B expression level was found not to be associated with the CAD-related SNPs at the 9p21 locus but associated with a number of other SNPs in this genomic region (32) . Our study differed from these previously studies, in that we examined VSMCs rather than blood cells. We found that in VSMCs, CDKN2A, CDKN2B and ANRIL expression levels were associated with a genotype for SNP rs1333049. Specifically, we found that p16 INK4a , p15 INK4b and ANRIL expression levels were lowest in VSMCs from homozygotes of the C allele which has been shown to be associated with increased risk of CAD in many studies (1, 6, 7) . In contrast, p14
ARF expression levels did not show an association with this SNP. This is not surprising since, although the risk genotype which reduces p16
INK4a
and p15
INK4b expression may also reduce p14 ARF expression, decreased p16
INK4a expression will increase the activity of the transcription factor E2F which in turn can up-regulate p14 ARF expression (27) and therefore offset the decrease in the p14 ARF expression level. There is evidence indicating that ANRIL plays a role in the transcriptional regulation of CDKN2A and CDKN2B, probably via its interaction with chromatin-associated factors that modulate chromatin methylation (18, 24) . Several different transcript variants of ANRIL have been reported (17, 18, 22, 25) . Previous studies have shown that expression levels of the long transcript of ANRIL were decreased and the short variants increased, in individuals homozygous for the 9p21 high-risk allele compared with those carrying two copies of the low-risk allele (17, 21) . In the present study, we examined the long transcript of ANRIL and, in agreement with the previous studies (17, 21) , found that its expression levels in VSMCs were lowest in homozygotes of the SNP rs1333049 C allele. Furthermore, similar to previous studies (17, 22, 23, 25) , we observed a correlation between the ANRIL long transcript and p16
INK4a and p15 INK4b expression levels. These findings are consistent with the hypothesis which has been proposed recently (17) that the 9p21 risk allele reduces expression of the ANRIL long transcript but increases expression of the short transcripts and that the short transcripts downregulate CDKN2A and CDKN2B expression.
Importantly, further to the finding that the SNP rs1333049 genotype was associated with p16
INK4a , p15 INK4b and ANRIL expression levels in VSMCs, we have discovered that it was also associated with the expression level of the cell proliferation marker PCNA and with the rate of VSMC proliferation, both being highest in VSMCs of the C/C genotype, indicating that the CAD risk allele (C allele) increases VSMC proliferation. Although this finding in cultured cells may not necessarily reflect the situation in vascular tissues in vivo, our study in coronary atherosclerotic plaques from different individuals shows that the risk allele (C allele) is associated with lower p15
INK4b expression in VSMCs and higher VSMC content in plaques. Thus, it is likely that the association between the 9p21 risk allele and increased risk of CAD is partly due to increased VSMC proliferation, since VSMC proliferation plays an important role in the pathogenesis of atherosclerosis (20) .
VSMCs and extracellular matrix proteins secreted by VSMCs constitute the main bulk of many atherosclerotic plaques (33, 34) . Accumulation of VSMCs and matrix proteins is a major factor for plaque growth (20) . However, plaques that contain a thick fibrous cap consisting largely of VSMCs and matrix proteins are less likely to rupture to cause thrombosis and acute ischaemic events such as myocardial infarction (35) . Genetic epidemiological studies have shown that the 9p21 risk allele is associated with atherosclerotic lesion development/progression and susceptibility to CAD (1,3,5 -8,12 ), but does not confer an increased risk of myocardial infarction in patients with coronary atherosclerosis (6, 36) . The finding of our study that the 9p21 variation is associated with VSMC proliferation is in concordance with these genetic epidemiological findings. In addition to CAD, other vascular diseases that have been shown to be associated with the 9p21 locus include abdominal aortic aneurysm (9) , intracranial aneurysm (9 -11), carotid atherosclerosis (12), ischaemic stroke (13) and peripheral vascular disease (14) . It is interesting that the 9p21 locus is associated with both atherosclerosis and aneurysms. In this study, in addition to confirming that VSMCs in the atherosclerotic lesions express p16
INK4a , p14 ARF and p15 INK4b as recently reported (28), we found that VSMCs in abdominal aortic aneurysmal lesions also express these cell cycle regulators. This information may be useful for future studies aimed to investigate the mechanism underlying the association of the 9p21 locus with aneurysms.
In summary, our study shows that the 9p21 variant is associated with CDKN2A, CDKN2B and ANRIL expression levels in VSMC primary cultures and p15
INK4b levels in VSMCs in atherosclerotic plaques, and with VSMC proliferation as well as VSMC content in plaques. These findings provide new insight into the mechanism underlying the well-established association between the 9p21 locus and risk of CAD.
MATERIALS AND METHODS

Immunohistochemical analysis
Sections of formaldehyde-fixed paraffin-embedded blocks of atherosclerotic arteries or aneurysmal arteries were subjected to double immunostaining for the VSMC marker SMA together with either p16 INK4a , p14 ARF or p15 INK4b . In brief, the sections were deparaffined with xylene and rehydrated with ethanol, and then incubated with 0.01 M sodium citrate to retrieve antigens, followed by incubation with an avidin and biotin blocking solution (Avidin Biotin Blocking systems, VectorLab), then a peroxidase blocking solution (3% H 2 O 2 ), and subsequently 10% goat serum (Dako). Thereafter, the sections were incubated with a primary antibody, which was either a rabbit anti-human p16
INK4a polyclonal antibody (Proteintech, 10883-1-AP), or a rabbit anti-human p14 ARF polyclonal antibody (Abcam, ab3642), or a rabbit antihuman p15
INK4b polyclonal antibody (Abcam, ab53034). The sections were then incubated with a biotin-conjugated goat anti-rabbit secondary antibody (Dako, E0432), followed by an incubation with avidin-conjugated horseradish peroxidase and then with 3,3 ′ -diaminodbenzidine (DAB). The sections were then incubated with a mouse anti-human SMA antibody conjugated with alkaline phosphatase (Sigma, A5691) and then with Fast Red (Sigma). In a second immunostaining procedure, the sections were prepared and incubated with the antibodies for p16 INK4a , p14 ARF and p15 INK4b as above, then with an anti-rabbit antibody conjugated with alkaline phosphatase (Sigma, A3687) and then with Fast Red. The sections were then incubated with a mouse anti-human SMA antibody (Sigma, A5228), followed by incubation with a biotin-conjugated goat anti-mouse secondary antibody (Sigma, B7264). The sections were then incubated with avidin-conjugated horseradish peroxidase and then with DAB. Subsequently, the sections were counterstained with haematoxylin.
Sections of formaldehyde-fixed paraffin-embedded blocks of atherosclerotic arteries were also subjected to double immunostaining for the VSMC marker SMA together with the cell proliferation marker Ki67. The sections were deparaffinized and re-hydrated in xylene and ethanol, respectively, and then transferred into 0.1 M citrate buffer for antigen retrieval, followed by incubation with 10% goat serum. The sections were then incubated overnight with primary antibodies which were a mouse anti-human SMA antibody (Dako, M-0635) and a rabbit anti-human Ki67 (Abcam, ab66155). After washing in phosphate-buffered saline, the sections were incubated with a biotinylated swine anti-rabbit Ig secondary antibody (Dako, E-0431) for 30 min and then with an anti-mouse Ig alkaline phosphatase-conjugated secondary antibody (Sigma, A-3562) for 30 min. After washing, the sections were incubated with avidin-conjugated horseradish peroxidase for 30 min and then with DAB for 5 min. This was followed by incubation with nitro-blue tetrazolium/ 5-bromo-4-chloro-3 ′ -indolyphosphate (NBT/BCIP). A methyl green counterstaining was then used before dehydrating and mounting the slides.
Slides were examined using an OLYMPUS BX61 microscope and images taken using a BX-PMTVC camera. Image analysis was done using ImagePro Software (Media Cybernetics) and blind to genotyping data. The study was approved by a National Research Ethics Service committee. The study fully complied with Good Clinical Practice guidelines and Tissue Act regulations.
Isolation, culture and immunocytochemical analyses of primary VSMCs
Arteries in umbilical cords were dissected out and the adventitia removed. They were then cut open, divided into small segments and placed onto gelatin-coated tissue culture flasks with the arterial media surface facing the tissue culture surface of the flasks. The flasks were incubated at 378C for 1.5 h to facilitate attachment of the arterial segments to the gelatin-coated tissue culture surface of the flasks. The arterial segments were then cultured in Dulbecco's modified Eagle's medium supplemented with 20% fetal bovine serum, 2% L-glutamine and penicillin/streptomycin at 378C with 5% CO 2 and 95% humidity. Once reaching 90% confluence, the VSMCs were harvested by trypsinization. The cells were then cultured in Smooth Muscle Cell Growth Medium (PromoCell) containing fetal calf serum (5%), epidermal growth factor (0.5 ng/ml), basic fibroblast growth factor (2 ng/ml) and insulin (5 mg/ml). Immunocytochemical analyses and
